At Home Use of Stimulation Suits for Managing MS Symptoms

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorDaphne Kos

About this trial

This study is being carried out at Multiple Sclerosis (MS) centers to evaluate whether a full-body stimulation suit at home can help people with Multiple Sclerosis (pwMS) reduce symptoms like spasticity (muscle stiffness) and ataxia (poor coordination), and improve daily functioning.

Can pwMS who experience spasticity or ataxia benefit from using a stimulation suit for 6 weeks?

Researchers will compare two groups: an intervention group (who will use the suit) and a control group (who will not use the suit).

Participants in the intervention group will:

* Wear the suit for 6 weeks in total every day or every other day (1 week during their MS center admission and 5 weeks at home). * Receive their usual care in addition to wearing the suit. * Undergo clinical tests at the MS center after 1 week and 6 weeks of stimulation.

Participants in the control group will:

* Receive their usual care. * Undergo clincial tests at the same time points as the other group.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Eligible participants must have ataxia or spasticity alongside impairments in upper or lower extremity physical function. MAS score ≥ 1 will be used as an inclusion criterion to determine the presence of spasticity. SARA score ≥ 4 will be used as an inclusion criterion to determine the presence of ataxia. Note: one of the two criteria (MAS score or SARA score) must be fulfilled for a pwMS to be eligible.

The patient must have the cognitive abilities to understand instructions and to be able to complete the questionnaires adequately

Diagnosis of multiple sclerosis.

Disqualifiers

Implanted devices (like pacemaker, Baclofen pump, neurostimulator, defibrillator, shunts, ECG equipment, electronic life support, high frequency operation equipment )

Change in disease modifying treatment within the last 3 months

Use of Botuline Toxine A within the last 3months

Recent relapse within the last 3 months

Trial design

Design model

Parallel

Treatments tested in this trial

  • electro-stimulation suit

    Device

    In EXOPULSE Mollii Suit is a multi-channel full-body suit with a low energy electrical stimulation - 20 Volt and 20 Hz. It generates 2 milliamp pulses (into 0-10,000 Ohms) with the following parameters: * Pulse width: variable between 25 and 170 μs. * Length of period: 50 ms. * Maximum amplitude: 20 V. It is composed of a control unit, a jacket and pants, with 58 embed-ded electrodes, in direct contact with the skin, and pre-positioned to stimulate 40 key muscle groups. The suit comes in different sizes. A trained medical staff pre-programs which nerves/muscles to be stimulated based on a clinical assessment of the user and the outcome is evaluated through standardized methods. The stimulation program is thus specific to each user.

  • Usual Care

    Other intervention

    The rehabilitation therapy that is being offered at the National MS Center Melsbroek, but somewhat reduced/adjusted to make time for initiation and follow-up of using the neuromodulation suit and potentially also during the weeks at home (i.e., rehabilitation being offered by municipalities).

Treatment groups

70 Participants
are divided into 2 treatment groups
Group A: stimulation suit groupExperimental treatment 2 interventions
Group B: usual careOther 1 intervention

Trial outcomes

Primary outcomes

1

NHPT+SSST score

The primary outcome will be a combined measure of upper and lower extremity motor function, consisting of the Nine Hole Peg Test and the Six Spot step test (labelled NHPT+SSST score). Values are expressed in seconds. A higher score, indicates a worse outcome.

Time frame
After one and six weeks of stimulation for the intervention group. The control group will be assessed at the same time points.

Secondary outcomes

1

Six spot step test (SSST)

Similar to the T25FW, the SSST is a quantitative measure of lower extremity function. The test contains a rectangular field with six circles on the floor following a criss-cross course. Five circles contain a block. The starting-point is the first circle, which does not contain a block. From there the patient walks to the other side of the field and kicks the blocks out of the five circles, as quickly as possible. The task is immediately administered again by having the patient walk back the same route. Both the dominant and non-dominant legs are tested twice. The Maximum value: 300.0 seconds A higher score indicates a worse outcome.

Time frame
SSST assessment will take place after weeks 1 and 6 of stimulation.
2

Nine Hole Peg Test (NHPT)

The Nine-Hole Peg Test (NHPT) is an assessment tool used to evaluate movement speed, particularly fine hand motor skills. The patient must take nine pegs from a container as quickly as possible and place them into the holes on a board. Afterwards, the patient must remove the pegs and return them to the container. The time taken to complete the task is measured. The patient may only use the hand being tested and must repeat the procedure for each peg individually (they are not allowed to pick up multiple pegs at once). A higher score indicates a worse outcome.

Time frame
NHPT assessment will take place after weeks 1 and 6 of stimulation.
3

Modified Ashworth Scale (MAS)

The Modified Ashworth Scale (MAS) is designed to objectively assess the degree of spasticity. The MAS measures the level of hypertonia in the left and right elbows and knees. The therapist evaluates the muscle tone and records the highest level of tone felt during five repetitions per joint, using a six-point scale (0 = no increase in muscle tone, 4 = limb rigid in flexion or extension and cannot be moved). A higher score indicates a worse outcome.

Time frame
MAS assessment will take place during screening, as they are used to determine eligibility and after weeks 1 and 6 of stimulation.
4

Scale for the Assessment and Rating of Ataxia (SARA)

SARA is a clinical scale which assesses a range of different impairments in cerebellar ataxia. The scale is made up of 8 items related to gait, stance, sitting, speech, finger-chase test, nose-finger test, fast alternating movements and heel-shin test. The minimum value: 0 The maximum value: 40 A higher score indicates a worse outcome.

Time frame
SARA assessment will take place during screening, as they are used to determine eligibility and after weeks 1 and 6 of stimulation.

Other outcomes

1

Multiple Sclerosis (MS) type

MS type: primary progressive (PP), secundary progressive (SP), relapsing remitting (RR), ..

Time frame
Will be collected (at baseline) when a partcipant is found eligible
2

age

Age (years)

Time frame
Will be collected at baseline when a partcipant is found eligible
3

sex

sex (m/v)

Time frame
Will be collected at baseline when a partcipant is found eligible
4

height

height (cm)

Time frame
Will be collected at baseline when a partcipant is found eligible

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Daphne Kos

Lead sponsor

Universitair Ziekenhuis Brussel

Sponsor institution

Danish MS Hospitals, Haslev and Ry

Collaborator

Universitair Ziekenhuis Brussel

Collaborator

National MS Center Melsbroek

Collaborator